A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetic and
pharmacodynamic properties of APG-2575 in patients with relapse or refractory chronic
lymphocytic leukemia and non-hodgkin's lymphoma.